Literature DB >> 19237084

Physician's guide to pharmacovigilance: terminology and causality assessment.

H S Rehan1, Deepti Chopra, Ashish Kumar Kakkar.   

Abstract

Adverse drug events can range from mild to life threatening reactions resulting in inconvenience or serious morbidity and mortality besides being a financial burden on the society. However clinicians often do not recognize this drug related harm. The terms used to describe these events with medication use cause much confusion. Moreover manifestations of adverse drug reactions can be non-specific making it difficult to differentiate from current illness. To determine the likelihood of relationship between the drug and the event assessment of causality is done. The purpose of this article is to review and clarify the terms encompassing the discipline of pharmacovigilance and also to outline the steps in causality assessment with the help of an actual case report.

Mesh:

Year:  2008        PMID: 19237084     DOI: 10.1016/j.ejim.2008.04.019

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  16 in total

1.  Semantic processing to identify adverse drug event information from black box warnings.

Authors:  Adam Culbertson; Marcelo Fiszman; Dongwook Shin; Thomas C Rindflesch
Journal:  AMIA Annu Symp Proc       Date:  2014-11-14

2.  Metronidazole-induced neurotoxicity presenting with sudden bilateral hearing loss, encephalopathy, and cerebellar dysfunction.

Authors:  Elmira Agah; Arman Habibi; Hamed Naderi; Abbas Tafakhori
Journal:  Eur J Clin Pharmacol       Date:  2016-10-15       Impact factor: 2.953

3.  Screening for Adverse Drug Events: a Randomized Trial of Automated Calls Coupled with Phone-Based Pharmacist Counseling.

Authors:  Gordon D Schiff; Elissa Klinger; Alejandra Salazar; Jeffrey Medoff; Mary G Amato; E John Orav; Shimon Shaykevich; Enrique V Seoane; Lake Walsh; Theresa E Fuller; Patricia C Dykes; David W Bates; Jennifer S Haas
Journal:  J Gen Intern Med       Date:  2018-10-05       Impact factor: 5.128

Review 4.  Identifying high-risk medication: a systematic literature review.

Authors:  Eva A Saedder; Birgitte Brock; Lars Peter Nielsen; Dorthe K Bonnerup; Marianne Lisby
Journal:  Eur J Clin Pharmacol       Date:  2014-03-27       Impact factor: 2.953

5.  DRESS with delayed onset acute interstitial nephritis and profound refractory eosinophilia secondary to Vancomycin.

Authors:  Paloma O'Meara; Rozita Borici-Mazi; A Ross Morton; Anne K Ellis
Journal:  Allergy Asthma Clin Immunol       Date:  2011-10-03       Impact factor: 3.406

6.  Consumers of natural health products: natural-born pharmacovigilantes?

Authors:  Rishma Walji; Heather Boon; Joanne Barnes; Zubin Austin; Sandy Welsh; G Ross Baker
Journal:  BMC Complement Altern Med       Date:  2010-02-25       Impact factor: 3.659

7.  Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature Review.

Authors:  Elisabetta Chessa; Matteo Piga; Alberto Floris; Mattia Congia; Ignazio Cangemi; Alessandro Mathieu; Alberto Cauli
Journal:  BioDrugs       Date:  2021-02-17       Impact factor: 5.807

8.  A prospective, observational study of adverse reactions to drug regimen for multi-drug resistant pulmonary tuberculosis in central India.

Authors:  Rohan Hire; A S Kale; G N Dakhale; Nilesh Gaikwad
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-09-01       Impact factor: 2.576

Review 9.  Health Professionals' Knowledge, Attitudes and Practices about Pharmacovigilance in India: A Systematic Review and Meta-Analysis.

Authors:  Akshaya Srikanth Bhagavathula; Asim Ahmed Elnour; Shazia Qasim Jamshed; Abdulla Shehab
Journal:  PLoS One       Date:  2016-03-24       Impact factor: 3.240

Review 10.  The Reporting Quality of Acupuncture-Related Infections in Korean Literature: A Systematic Review of Case Studies.

Authors:  Tae-Hun Kim; Jung Won Kang; Wan-Soo Park
Journal:  Evid Based Complement Alternat Med       Date:  2015-11-03       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.